UBX
Unity Biotechnology
Delisted
UBX was delisted on the 8th of July, 2025.
72 hedge funds and large institutions have $24.1M invested in Unity Biotechnology in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
11% more funds holding
Funds holding: 65 → 72 (+7)
2.99% more ownership
Funds ownership: 1.36% → 4.35% (+3%)
Holders
72
Holding in Top 10
3
Calls
$5.75M
Puts
$24K
Top Buyers
| 1 | +$5.08M | |
| 2 | +$3.97M | |
| 3 | +$2.61M | |
| 4 |
EAM
Empery Asset Management
New York
|
+$1.74M |
| 5 |
ACM
Altium Capital Management
New York
|
+$1.69M |
Top Sellers
| 1 | -$361K | |
| 2 | -$202K | |
| 3 | -$127K | |
| 4 |
Two Sigma Advisers
New York
|
-$118K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$90K |